Demographics, clinical characteristics, and AKI metric measurements
In total, 33,352 patient encounters met KDIGO criteria within the first 48 hours after ICU admission. After excluding the patients according to the exclusion criteria, the final analysis cohort consisted of 3,989 eligible patients (Fig. 1). In the analytic cohort, the average age was 65.91±15.08 years old, male patients accounted for 53.9% (n=2150), white patients occupied 72.7% (2903), and the median SOFA score was 5.82±3.41. Of these, the cohort was divided into two groups: AKI recovery group (n=2,947, 73.9%) vs. AKI non-recovery (n=1,042, 26.1%). Of the recruited patients, 923 were stage 1 (817 AKI recovery vs. 106 AKI non-recovery), 1,978 were stage 2 (1,625 AKI recovery vs. 353 AKI non-recovery), 1,088 were stage 3 (505 AKI recovery vs. 583 AKI non-recovery). The average recovery time was 2.1 days for total recovery critically ill patients. Baseline demographics, clinical characteristics, interventions, and outcomes were outlined in Table 1.
Table 1
Distribution of baseline characteristics between AKI recovery and non-recovery group
Characteristic | Total (n=3,989) | AKI recovery (n=2,947) | AKI non-recovery (n=1,042) | p value |
Age, y, mean ± SD | 65.91±15.08 | 65.75±14.68 | 66.38±16.16 | 0.026* |
Male Gender, n (%) | 2150 (53.9) | 1601 (54.3) | 549 (52.7) | 0.381 |
Ethnicity, n (%) | 0.009** |
White | 2903 (72.7) | 2177 (73.9) | 726 (69.7) | |
Asian | 78 (1.9) | 59 (2) | 19 (1.8) | |
Black | 273 (6.8) | 195 (6.6) | 78 (7.5) | |
Hispanic | 120 (3) | 90 (3.1) | 30 (2.9) | |
Unknown | 514 (12.9) | 351 (11.9) | 163 (15.6) | |
Alcohol Abuse, n (%) | 336 (0.08) | 240 (0.08) | 96 (0.09) | 0.316 |
SOFA Score, mean ± SD | 5.82±3.41 | 5.31±3.18 | 7.24±3.63 | <0.001*** |
Comorbidities, n (%) |
CVD | 1367 (34.3) | 1105 (37.49) | 262 (25.14) | <0.001*** |
ARDS | 968 (24.3) | 606 (20.6) | 362 (34.7) | <0.001*** |
Hypertension | 2517 (63.1) | 1913 (64.9) | 604 (57.9) | <0.001*** |
Chronic Pulmonary Disease | 851 (21.3) | 606 (20.6) | 362 (34.7) | 0.0284* |
Heart Failure | 413 (10.4) | 311 (10.6) | 102 (9.8) | 0.524 |
Organ Dysfunction, n (%) | 2386 (59.8) | 1562 (53) | 824 (79) | <0.001*** |
Sepsis, n (%) | 547 (13.7) | 335 (11.4) | 212 (20.3) | <0.001*** |
Vital Signs |
HR min 24h (bpm), M (P25-P75) | 71 (61-82) | 71 (61-81) | 72 (62-83) | 0.112 |
HR 24h (bpm), M (P25-P75) | 103 (91-118) | 103 (91-118) | 103 (90-119) | 0.949 |
RR min 24h (bpm), M (P25-P75) | 12 (10-14) | 12 (10-14) | 12 (10-15) | <0.001*** |
RR max 24h (bpm), M (P25-P75) | 12 (10-15) | 27 (24-31) | 28 (24-32) | 0.165 |
MAP min 24h (mmHg), M (P25-P75) | 58.39 (52.72-65.06) | 58.5 (53.09-65.22) | 57.98 (51.31-64.63) | 0.013* |
MAP max 24h (mmHg), M (P25-P75) | 102 (92-115) | 102 (92-115) | 102 (90-115.92) | <0.001*** |
SBP min <90 (mmHg), M (P25-P75) | 2373 (59.5) | 1785 (60.6) | 588 (56.4) | 0.021* |
T max >37.3 (℃), n (%) | 2661 (66.7) | 2049 (69.5) | 612 (58.7) | <0.001** |
T max 24h, mean ± SD | 37.66±0.807 | 37.7±0.768 | 37.57±0.899 | <0.001** |
SpO2 1st, mean ± SD | 91.13±7.91 | 91.54±6.94 | 89.97±10.13 | <0.001*** |
Urinary variables |
Urine Ratio 6h, M (P25-P75)] | 0.46 (0.35-0.59) | 0.46 (0.37-0.59) | 0.43 (0.25-0.65) | <0.001*** |
Proteinuria 24h, M (P25-P75) | 146.9 (90-160) | 123.5 (90-135) | 213.2 (130-160) | <0.001*** |
Pre-AKI Urine Volume 24h, M (P25-P75) | 1000 (632-1407) | 1000 (619-1644) | 1000.5 (725- 1000.5) | <0.001*** |
Post-AKI Urine Volume 24h, M (P25-P75) | 1416 (870-2170) | 1530 (1010-2290) | 997.5 (489.2-1728.8) | <0.001*** |
Post-AKI Urine Volume min 24h, M (P25-P75) | 20 (10-30) | 20 (10-30) | 15 (5-30) | <0.001*** |
Serum laboratory variables, M(P25-P75) |
SCr 1st, (µmol/l) | 1.2 (0.9-1.7) | 1.1 (0.9-1.4) | 1.8 (1.3-3) | <0.001*** |
SCr max 24h, (µmol/l) | 1.3 (1-2) | 1.2 (0.9-1.5) | 2.3 (1.6-3.5) | <0.001*** |
SCr min 36h, (µmol/l) | 1 (0.8-1.4) | 0.9 (0.8-1.1) | 1.7 (1.1-2.8) | <0.001*** |
SCr max 36h, (µmol/l) | 1.3 (1-1.9) | 1.2 (1-1.4) | 2.3 (1.5-3.6) | <0.001*** |
Post-AKI SCr max 48h, (µmol/l) | 1.4 (1.1-2.2) | 1.3 (1-1.6) | 2.6 (1.8-4) | <0.001*** |
Hemoglobin min 24h, (g/dL) | 9.5 (8-11) | 9.5 (8-11.2) | 9.4 (8-10.9) | 0.006** |
Hemoglobin max 24h, (g/dL) | 12.1 (10.8-13.5) | 12.4 (11.1-13.6) | 11.4 (10.2-12.8) | <0.001*** |
Platelet min, (× 109/L) | 165 (116-225) | 165 (119.5-227) | 165 (107-220) | 0.013* |
Platelet max 24h, (× 109/L) | 198 (148-261) | 200 (152-262) | 196 (133-260) | 0.008** |
Bicarbonate min 24h, (mmol/L) | 22 (18-24) | 22 (19-24) | 20 (16-23) | <0.001*** |
Bicarbonate max 24h, (mmol/L) | 24 (22-27) | 25 (22-27) | 23 (20-26) | <0.001*** |
Cardiac Troponin T max, (µg/L) | 0.11 (0.11-0.15) | 0.11 (0.11-0.13) | 0.11 (0.11-0.21) | 0.195 |
Post-AKI Cardiac Troponin T 24h, (µg/L) | 0.3 (0.3- 0.35) | 0.3 (0.3- 0.32) | 0.3 (0.3- 0.62) | <0.001*** |
Prothrombin Time min 24h, (sec) | 14.1 (13.4-15.1) | 14.1 (13.3-14.9) | 14.1 (13.5-16) | <0.001*** |
Prothrombin Time max 24h, (sec) | 15.2 (14-17) | 15.1 (13.7-17.2) | 15.6 (13.9-18.7) | <0.001*** |
Total Bilirubin min 24h, (mg/dL) | 0.7 (0.6-0.7) | 0.7 (0.65-0.7) | 0.7 (0.5-1) | <0.001*** |
Total Bilirubin max 24h, (mg/dL) | 0.8 (0.7-0.8) | 0.8 (0.75-0.8) | 0.8 (0.6-1.2) | <0.001*** |
Albumin max 24h, (g/dL) | 3 (3-3.001) | 3 (2.6-3.5) | 3 (2.5-3.4) | <0.001*** |
Albumin min, (g/dL) | 3.1 (3-3.1) | 3.1 (3-3.1) | 3.1 (2.9-3.1) | <0.001*** |
Lactate min 24h, (mmol/L) | 1.5 (1.2-1.8) | 1.5 (1.2-1.8) | 1.5 (1.2-1.9) | <0.001*** |
Lactate max 24h, (mmol/L) | 2.5 (2.1-3) | 2.5 (1.7-3.8) | 2.5 (1.6-4.6) | <0.001*** |
Chloride min 24h, (mmol/L) | 103 (100-106) | 103 (100-106) | 103 (99-107) | 0.022* |
Base Excess min 24h, (mmol/L) | -4 (-6--2) | -4 (-5--1) | -4 (-8--3) | <0.001*** |
Interventions |
RRT Duration, M (P25-P75) | 0.712±3.3 | 0.264±2.1 | 1.976±5.22 | <0.001*** |
RRT Times, M (P25-P75) | 18.13±9.5 | 8.159±7.4 | 46.31±13.5 | <0.001*** |
Mechanical Ventilation, n (%) | 1654 (41.5) | 1122 (38.1) | 532 (51) | <0.001*** |
Vasopressor Duration, M(P25-P75) | 29.66 (22.85-38.25) | 26 (10.75-55.06) | 42.83 (14.09-93.83) | 0.3699 |
AKI Stage by SCr Criteria, n (%) | <0.001*** |
0 | 1183 | 1146 (38.9) | 37 (3.6) | |
1 | 1580 | 1332 (45.2) | 248 (23.8) | |
2 | 594 | 288 (9.8) | 306 (29.4) | |
3 | 632 | 181 (6.1) | 451 (43.3) | |
AKI Stage, n (%) | <0.001*** |
1 | 923 (23.1) | 817 (27.7) | 106 (11.5) | |
2 | 1978 (49.6) | 1625 (55.1) | 353 (17.8) | |
3 | 1088 (27.3) | 505 (17.1) | 583 (53.6) | |
Legend: AKI = acute kidney disease; ARDS = acute respiratory distress syndrome; CVD = cardiovascular disease; HR = heart rate; MAP = mean arterial pressure; RR = respiratory rate; RRT = renal replacement therapy; SBP = systolic pressure; SCr = serum creatinine; SOFA Score = sepsis-related organ failure assessment score; SpO2 = peripheral oxygen saturation; T = temperature. p: ***< 0.001, ** <0.01, *: <0.05 |
Features Selected and model Comparison in Renal Function Recovery
Patients with AKI non-recovery were of more comorbidities, higher AKI stage, total bilirubin, prothrombin time, proteinuria, cardiac troponin T within 24 hours after AKI diagnosis, and higher maximum SCr within 48 hours from diagnosis AKI compared to those diagnosed with those AKI recovery patients (p<0.001). Patients belonging to the AKI non-recovery group had an increased proportion of needing mechanical ventilation and RRT (p<0.001). In addition, more patients with AKI non-recovery had a higher temperature but lower SpO2 (p<0.001) (Table 1).
The results of logistic regression analysis were outlined in Table 2. Among 3,989 AKI recovery patients, we randomly selected 3,561 patients (90%) for model derivation. As expected, patients who were elderly (OR = 1.022, 95% CI 1.02-1.03), SBP minimum <90mmHg (OR = 0.665, 95% CI 0.55-0.81), lower post-AKI urine volume within 24 hours (OR = 0.999, 95% CI 0.99-0.99), higher SCr minimum within 36 hours (OR = 1.508, 95% CI 1.33-1.73), higher post-AKI troponin T within 24 hours (OR = 1.007, 95% CI 1-1.01), higher lactate maximum with 24 hours (OR = 1.049, 95% CI 1-1.09), or with higher AKI stage (OR = 3.097, 95% CI 2.73-3.52) demonstrated increased odds in failing to recover from AKI.
Table 2
Univariate and multivariate logistic regression analysis for AKI recovery
| Univariate analysis | Multivariate analysis |
Variables | OR (95%CI) | P | OR (95%CI) | P |
Age | 1.004 (0.99-1.01) | 0.089 | 1.022 (1.02-1.03) | <0.001*** |
Gender | 0.939(0.81-1.09) | 0.405 | | |
Ethnicity | 1.051 (1-1.1) | 0.037* | | |
Alcohol Abuse | 1.121(0.86-1.45) | 0.395 | | |
SOFA Score | 1.174 (1.15-1.2) | <0.001*** | | |
CVD | 0.573 (0.48-0.68) | <0.001*** | | |
ARDS | 2.024 (1.72-2.38) | <0.001*** | | |
Hypertension | 0.761 (0.65-0.89) | 0.0004*** | | |
Chronic Pulmonary Disease | 0.784 (0.65-0.95) | 0.0116* | | |
Heart Failure | 0.933 (0.73-1.19) | 0.586 | | |
Organ Dysfunction | 3.207 (2.7-3.82) | <0.001*** | | |
Sepsis | 1.904 (1.56-2.31) | <0.001*** | | |
HR min 24h (bpm) | 0.966 (0.93-0.99) | 0.038* | | |
HR max 24h (bpm) | 0.814 (0.78-0.85) | <0.001*** | | |
MAP min 24h (mmHg) | 0.988 (0.98-0.99) | 0.002** | | |
SBP min <90 (mmHg) | 0.854 (0.74-0.99) | 0.0409* | 0.665 (0.55-0.81) | <0.001*** |
T max >37.3 (℃) | 0.631 (0.54-0.74) | <0.001*** | | |
SpO2 1st | 0.979 (0.96-0.99) | 0.002** | | |
Urine Ratio 6h | 1.01 (0.98-1.04) | 0.545 | | |
Proteinuria 24h | 1 (1-1.01) | 0.001** | | |
Pre-AKI Urine volume 24h | 0.99 (0.9-0.99) | <0.001*** | | |
Post-AKI Urine volume 24h | 0.99 (0.9-0.99) | <0.001*** | 0.999 (0.99-0.99) | <0.001*** |
Post-AKI Urine Volume min 24h | 1 (0.99-1.01) | 0.759 | | |
SCr 1st | 2.037 (1.88-2.21) | <0.001*** | | |
SCr max 24h, (µmol/l) | 2.277 (2.1-2.47) | <0.001*** | | |
SCr min 36h, (µmol/l) | 3.756 (3.33-4.26) | <0.001*** | 1.508 (1.33-1.73) | <0.001*** |
SCr max 36h, (µmol/l) | 2.549 (2.34-2.78) | <0.001*** | | |
Post-AKI SCr max 48h, (µmol/l) | 2.467 (2.28-2.67) | <0.001*** | | |
Hemoglobin min 24h, (g/dL) | 0.966 (0.93-0.99) | 0.038* | | |
Hemoglobin max 24h, (g/dL) | 0.814 (0.78-0.85) | <0.001*** | | |
Platelet min 24h, (× 109/L) | 0.999 (0.998-0.999) | 0.01** | | |
Platelet max 24h, (× 109/L) | 1.308 (1.12-1.54) | 0.0009*** | | |
Bicarbonate min 24h, (mmol/L) | 0.91 (0.9-0.93) | <0.001*** | | |
Bicarbonate max 24h, (mmol/L) | 0.903 (0.89-0.92) | <0.001*** | | |
Cardiac Troponin T max 24h, (µg/L) | 1.002 (0.99-1.01) | 0.496 | | |
Post-AKI Cardiac Troponin T 24h, (µg/L) | 1.01 (1-1.02) | 0.001** | 1.007 (1-1.01) | 0.018* |
Prothrombin Time min 24h | 1.048 (1.03-1.07) | <0.001*** | | |
Prothrombin Time max 24h | 1.023 (1.01-1.03) | <0.001*** | | |
Total Bilirubin min 24h | 1.066 (1.04-1.09) | <0.001*** | | |
Total Bilirubin max 24h | 1.059 (1.04-1.08) | <0.001*** | | |
Albumin min 24h | 0.676 (0.58-0.79) | <0.001*** | | |
Albumin max 24h | 0.809 (0.67-0.98) | 0.031* | | |
Lactate max 24h | 1.085 (1.05-1.12) | <0.001*** | | |
RRT Duration | 1.196 (1.16-1.24) | <0.001*** | | |
Mechanical ventilation | 1.729 (1.49-2.01) | <0.001*** | | |
AKI Stage | 4.004 (3.64-4.42) | <0.001*** | 3.097 (2.73-3.52) | <0.001*** |
Legend: AKI = acute kidney disease; ARDS = acute respiratory distress syndrome; CVD = cardiovascular disease; HR = heart rate; MAP = mean arterial pressure; RR = respiratory rate; RRT = renal replacement therapy; SBP = systolic pressure; SCr = serum creatinine; SOFA Score = sepsis-related organ failure assessment score; SpO2 = peripheral oxygen saturation; T = temperature. p: ***< 0.001, ** <0.01, *: <0.05 |
Moreover, according to the analysis results of each variables’ contribution by XGBoost model, maximum SCr within 48 hours from diagnosis of AKI, AKI stage, Scr minimum within 36 hours, age, post-AKI urine volume within 24 hours, were the top 5 essential predictors for predicting renal function recovery (Fig. 2). Fig. 3 showed the training process of the XGBoost model.
A total of 398 (10%) patients were included in the model validation phase. The discrimination was appraised using AU-ROC and PR in the model development and validation phase. The XGBoost algorithm showed significantly greater discrimination than the traditional logistic regression model, with a higher and more narrowed 95% confidence interval (AU-ROC, 0.92; 95% CI 0.89-0.94 vs. 0.88; 95% CI 0.84-0.92, respectively) (Fig. 4). Table 3 describes the obvious model measures for the two models in identifying the AKI recovery and non-recovery status. When considering sensitivity and precision to predict an independent testing set, the XGBoost performed a more balanced result than the logistic regression.
Table 3
Model performance in development cohort for AKI recovery.
Model Performance | Logistic regression | XGBoost |
Accuracy | 0.8518 | 0.8492 |
Sensitivity | 0.9628 | 0.9122 |
Specificity | 0.5294 | 0.6667 |
Precision | 0.8563 | 0.8882 |
Recall | 0.9662 | 0.9122 |
AU-ROC (95%CI) | 0.8828 (0.84-0.92) | 0.9178 (0.89-0.94) |
Model Establishment and Comparison in Renal Function Recovery Time
The 2,947 recovery population was randomly split into a training and validation cohort consisting of 2,654 (90%) and 293 (10%) recovery patients. We performed the Pearson correlation analysis, which showed that SCr minimum within 36 hours, AKI Stage, albumin minimum and other 32 variables were associated with recovery duration increases (r =0.32 p < 0.001, r = 0.26 p < 0.001, r = -0.1 p = 0.009, respectively). Therefore, we performed these factors in a multivariate linear regression model, which revealed SCr alone explained 11.09% of the variation, increasing AKI Stage, and minimum albumin explained 12.61% of the variation. The final linear regression model showed the best model performance (R2 = 0.2006, RMSE = 4.177) (Table 4).
Table 4
Features selected in the multivariate linear regression model (n = 2,654)
Models | Predictors | Coefficients | R2 | Increased R2 | p-Value |
| | B | SE | | | |
1 | SCr min 36h | 1.948 | 0.107 | 0.1109 | | <.001*** |
2 | SCr min 36h | 1.549 | 0.125 | 0.1261 | 0.0152 | <.001*** |
| AKI Stage by SCr Criteria | 0.538 | 0.097 | | | <.001*** |
| Albumin min | -0.48 | 0.148 | | | <0.001*** |
3 | SCr min 36h | 1.374 | 0.123 | 0.2006 | 0.0745 | <0.001*** |
| AKI Stage by SCr Criteria | 0.504 | 0.099 | | | <0.001*** |
| Albumin min | -0.705 | 0.220 | | | 0.001** |
| Post-AKI Urine volume 24h | 0.001 | 0.001 | | | 0.001** |
| Hemoglobin min 24h | 0.054 | 0.031 | | | 0.079 |
| ARDS | 0.471 | 0.194 | | | 0.015* |
| RRT Duration | 0.277 | 0.033 | | | <0.001*** |
| Mechanical Ventilation | 1.047 | 0.165 | | | <0.001*** |
| Prothrombin Time max 24h | 0.049 | 0.014 | | | 0.001** |
| Bicarbonate min | 0.061 | 0.016 | | | <0.001*** |
| Albumin max 24h | 0.585 | 0.280 | | | 0.037* |
| Prothrombin Time min | -0.073 | 0.025 | | | 0.004** |
| Hypertension | -0.301 | 0.141 | | | 0.033* |
| Total Bilirubin max 24h | 0.015 | 0.024 | | | 0.524 |
| Ethnicity | 0.057 | 0.044 | | | 0.192 |
Legend: AKI = acute kidney disease; ARDS = acute respiratory distress syndrome; RRT = renal replacement therapy; SCr = serum creatinine; SOFA Score = sepsis-related organ failure assessment score. p: ***< 0.001, ** <0.01, *: <0.05 |
We also built an overall ExtraTrees model, which contained 2,654 AKI recovered patients who showed better predictive ability (R2 = 0.3626, RMSE =2,932). Gender-specific ExtreTrees classifier revealed the higher predictive performance (R2 = 0.3411, RMSE =2,978), which showed some similarly essential predictors with linear regression, such as SCr, urine volume, AKI Stage, RRT duration, and mechanical ventilation (Fig. 5). Table 5 compares model performance using R2 and RMSE.
Table 5
Model performance in development cohort for AKI recovery time.
Model Performance | R2 | RMSE |
Linear regression | 0.2006 | 4.177 |
Extratrees overall | 0.3411 | 2.978 |
Extratrees gender-specific | 0.3623 | 2.932 |